Clinical Trials

BreastGastrointestinalThoracic

396 enrolled

Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT07403136 2026-04-15

Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC

Phase 2 Suspended

104 enrolled

Esophageal Squamous Cell Carcinoma

NCT07519486 2026-04-15

INS-ESCC-CT

118 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06885814 2026-04-14

Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma

30 enrolled

Esophageal Squamous Cell Carcinoma

NCT07205731 2026-04-14

SAFE ESO

95 enrolled

Esophageal Squamous Cell Carcinoma, Neoplasms

NCT03957590 2026-04-13

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

Phase 3 Completed

370 enrolled 17 charts

Esophageal Squamous Cell Carcinoma

NCT07217171 2026-04-13

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

GastrointestinalGenitourinary

160 enrolled

Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Urinary Bladder Neoplasms

NCT07284186 2026-04-13

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Phase 2 Active not recruiting

155 enrolled

GastrointestinalThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT05945823 2026-04-09

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

53 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT04389632 2026-04-07

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

1,006 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT07090499 2026-04-07

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

GastrointestinalGenitourinaryHead & NeckThoracic

310 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Pancreatic Neoplasms

NCT06657144 2026-04-06

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

154 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT07277413 2026-04-03

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

GastrointestinalGenitourinaryOther solid neoplasmThoracic

260 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Mesothelioma, Neoplasm Metastasis, Recurrence

NCT06654297 2026-04-02

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas

Phase 1 Active not recruiting

6 enrolled

Phase 2 Not yet recruiting

Esophageal Squamous Cell Carcinoma

NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT06780111 2026-03-31

MK-3475-06E

298 enrolled

Esophageal Squamous Cell Carcinoma

NCT07503808 2026-03-31

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

BreastGastrointestinalGynecologicHead & NeckThoracic

150 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05799274 2026-03-30

RAD301

GastrointestinalGynecologicThoracic

9 enrolled

Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT06828588 2026-03-30

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Phase EARLY_PHASE1 Not yet recruiting

30 enrolled

BreastGastrointestinal

Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms

NCT06971848 2026-03-30

ETCABIO

Phase NA Not yet recruiting

70 enrolled

GastrointestinalLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellThoracic

Immunoglobulin Light-chain Amyloidosis, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Carcinoma, Bronchogenic, Heart Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Follicular, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Cholangiocarcinoma, Neoplasms, Plasma Cell

NCT04785820 2026-03-27

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Phase 2 Completed

190 enrolled 40 charts

Esophageal Squamous Cell Carcinoma

NCT07189871 2026-03-27

BetaBart

BreastGastrointestinalGynecologicHead & NeckThoracic

61 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06535607 2026-03-24

eVOLVE-02

GastrointestinalGynecologicHead & Neck

257 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Uterine Cervical Neoplasms

NCT07109726 2026-03-23

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

BreastGastrointestinalGynecologicHead & Neck

205 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT07218003 2026-03-23

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Phase 1 Enrolling by invitation

149 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05319730 2026-03-20

MK-3475-06B

230 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07481058 2026-03-20

KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer

60 enrolled

Esophageal Squamous Cell Carcinoma

NCT03301454 2026-03-18

E-DIS2

Phase 2 Terminated

15 enrolled

Phase 1/2 Active not recruiting

Esophageal Squamous Cell Carcinoma

NCT04140500 2026-03-18

Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

170 enrolled

DermatologicGastrointestinalThoracic

Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT07457528 2026-03-11

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

46 enrolled

Phase 3 Not yet recruiting

Esophageal Squamous Cell Carcinoma

NCT07463573 2026-03-11

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

466 enrolled

Esophageal Squamous Cell Carcinoma

NCT03322267 2026-03-06

Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence

Phase 2 Completed

26 enrolled 6 charts

Phase 2 Not yet recruiting

Esophageal Squamous Cell Carcinoma

NCT07452601 2026-03-05

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

90 enrolled

Esophageal Squamous Cell Carcinoma

NCT06747585 2026-03-03

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

GastrointestinalHead & Neck

170 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT06452602 2026-02-27

Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.

60 enrolled

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07039162 2026-02-27

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT07437898 2026-02-27

Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study

42 enrolled

Esophageal Squamous Cell Carcinoma

NCT05208762 2026-02-23

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

714 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04868877 2026-02-19

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Phase 1/2 Active not recruiting

194 enrolled

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT05312372 2026-02-17

S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC

Phase 1/2 Withdrawn

GastrointestinalGenitourinaryHead & NeckThoracic

Esophageal Squamous Cell Carcinoma

NCT05462873 2026-02-17

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Phase 1 Terminated

30 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT07085091 2026-02-17

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

GastrointestinalHead & NeckThoracic

170 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT07403435 2026-02-11

Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC

Phase 2 Not yet recruiting

22 enrolled

Esophageal Squamous Cell Carcinoma

NCT00628368 2026-02-10

Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer

Phase NA Completed

160 enrolled